Among adults with #PTSD, intermittent oral TSND-201 treatment produced greater reductions in PTSD symptoms than placebo and was well tolerated, supporting its potential as a rapid-acting, durable pharmacologic option.
https://t.co/7v0zqXFkWV
Excited to share that Transcend Therapeutics raised $40 million in Series A funding. This fundraise will accelerate development of our lead compound and bring us a step closer to offering life-saving treatments to the 1 billion people who suffer from mental health illness.
Wall Street is betting millions of dollars on psychedelic drugs that could treat mental illness for a fraction of what better-known therapies cost https://t.co/KHOgyGe1oN
Thank you @Forbes for the honor. Proud to represent Transcend Therapeutics, where we work to provide better treatment options to those suffering from PTSD, depression, and other neuropsychiatric diseases. #ForbesUnder30 https://t.co/hDA6I0p9Jf
Great primer on psychedelics in Cell written by my cofounder Dr. Ben Kelmendi, @DrChrisPitt, @kwanalexc, and @akaye, all involved with the Yale Center for Psychedelic Science.
A primer article about #psychedelics. We wanted a concise and accurate piece to share with undergraduates, journalists, and others who want to know more. Free link via @CurrentBiology: https://t.co/1O6YEwsetl @YalePsych@YaleMed 1/n
Thich Nhat Hanh, rest in peace. Your books changed my life, and were my first exposure to Buddhism during some of my worst moments. May you have broken your cycle of samsara.